Experimental work has shown, for HPAI and H5/H7 LPAI, that properly administered vaccines protect
against clinical signs and mortality, reduces virus shedding and increases resistance to infection,
protects from diverse field viruses within the same haemagglutinin subtype, protects from low and high
challenge exposure, and reduces excretion and thus contact transmission of challenge virus